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Background: While tamoxifen activity is mainly due to endoxifen and the concentration of this active metabolite is,
in part, controlled by CYP2D6 metabolic status, clinical correlative studies have produced mixed results.
Findings: In an exploratory study, we determined the CYP2D6 metabolic status and plasma concentrations of
endoxifen among 224 Filipino and Vietnamese women participating in a clinical trial of adjuvant hormonal therapy
for operable breast cancer. We further conducted a nested-case–control study among 48 women (half with
recurrent disease, half without) investigating the relationship of endoxifen concentrations and recurrence of disease.
We found a significant association of reduced endoxifen plasma concentrations with functionally important CYP2D6
genotypes. High endoxifen concentrations were associated with higher risk of recurrence; with a quadratic trend
fitted to a stratified Cox proportional hazards regression model, the likelihood ratio p-value was 0.002. The trend
also showed that in 8 out of 9 pairs with low endoxifen concentrations, the recurrent case had lower endoxifen
levels than the matched control.
Conclusions: This exploratory analysis suggests that there is an optimal range for endoxifen concentrations to
achieve favorable effects as adjuvant therapy. In particular, at higher concentrations (>70 ng.ml), endoxifen may
promote recurrence.Introduction
Although in vitro and in vivo studies have strongly
suggested that tamoxifen activity is mainly due to endoxifen
and that the concentration of this active metabolite is in
part controlled by CYP2D6 metabolic status, clinical cor-
relative studies have produced mixed results. The lack of
consistent results may be in part due to the retrospective
nature of most of the clinical studies. In addition, endoxifen
plasma concentrations are highly variable among patients.
While CYP2D6 is the main enzyme catalyzing the forma-
tion of endoxifen from N-desmethyltamoxifen, CYP2D6
metabolic status only accounts for 10-19% of the variability* Correspondence: richardibcrf@gmail.com
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in any medium, provided the original work is p(Desta et al. 2004; Jin et al. 2005). Thus, over 80% of
endoxifen inter-patient variability remains unexplained by
CYP2D6. In light of the possibility that multiple pathways
control endoxifen plasma concentrations, and given that
the pharmacogenetic studies so far reported are not consist-
ent, it is likely that the absolute endoxifen concentrations
better predict tamoxifen activity in patients. The multip-
licity of studies available evaluating pharmacogenomic
hypotheses with tamoxifen have investigated CYP2D6
genotypes and outcomes, and these considerations likely
explain why these reports do not provide a clear picture of
the relationship (Dezentjé et al. 2009; Hayes et al. 2008;
Kiyotani et al. 2010; Lash and Rosenberg 2010).Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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than a single gene variation, may be a better biomarker
of tamoxifen response.
In the context of a clinical trial where all patients were
receiving tamoxifen as part of their adjuvant therapy for
hormone receptor-positive breast cancer, here we report
preliminary data addressing associations of disease re-
currence with CYP2D6 genotypes and endoxifen plasma
concentrations, in the first 224 Asian subjects we have
studied in the trial.
Methods and patients
Patients
Provisional IRB approval was first obtained at the princi-
pal investigator’s (RRL) American institution following
which specific approval was obtained from in-country
appropriate IRBs in the Philippines and Vietnam, and at
co-investigators’ institution (Indiana University), again
following which the principal investigator’s institution
provided final approval. The parent clinical trial whose
participants were recruited was similarly approved by the
foreign and principal investigator’s IRBs.
This ancillary study was begun after the parent clinical
trial had accrued 40% of subjects (total accrual =740).
Some patients on the parent trial refused participation in
the current ancillary study. Thus the patients entering the
current study are not representative of all patients en-
tering the parent trial. The parent trial is a randomized
clinical trial evaluating the impact of the timing of surgical
oophorectomy in the menstrual cycle on outcomes from
operable, hormone receptor positive breast cancer. All
patients in the trial underwent surgical oophorectomy on
the same day as their primary breast surgery, and began
tamoxifen 20 mg per day within five days after this.
We have reasons to believe that the compliance with tam-
oxifen administration (Nolvadex, supplied by AstraZeneca)
is high and thus this factor seems less likely to affect the
current pharmacogenetic studies. Specifically, patients are
expected to return at 3-month intervals to get their drug,
which is free. We have logs recording patient collection of
tamoxifen medication. The tamoxifen, endoxifen and other
metabolite levels in the 224 individual patients studied to
date (vide infra) are all such that regular tamoxifen con-
sumption must be occurring. Patients are not taking any
drugs believed to interfere with tamoxifen metabolism
which issue has confounded reported studies in western
populations.
Plasma, leukocyte and serum specimens after four or
more months of tamoxifen treatment were obtained in
light-shielded tubes from 224 Vietnamese and Filipino
patients. The specimens were frozen at −70 degrees C,
and shipped frozen in liquid nitrogen canisters to the In-
diana University co-investigators. The logistics of sample
collection, storage and transport from these foreigncountries to the US have been carefully conducted and
are validated by the preliminary data we generated. By four
months after initiation of tamoxifen, steady-state concen-
trations of tamoxifen and metabolites are achieved (Jin et al.
2005). Given that the volume of distribution of tamoxifen
and metabolites is large, with long half-lives, diurnal and
day-to-day variation in these concentrations in an individual
patient is minimal (Lash and Rosenberg 2010).
Laboratory methods
The CYP2D6 gene is highly polymorphic, with over 70
alleles that exhibit functional consequences identified. We
have genotyped for CYP2D6 variants relevant to Filipino
and Vietnamese populations.
Genomic DNA was isolated from the leukocytes using
the QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, CA,
USA) and stored at −20°C until use. The DNA concen-
trations were measured by Quant-iT DNA Broad Range
Kit (Invitrogen, Carlsbad, CA, USA). The DNA was
diluted to10 ng/μl and used for performing the CYP2D6
genotyping assays. The genotyping was performed for
CYP2D6 alleles *2, *3, *4, *5, *6, *10, and *41 using the
predeveloped TaqMan Genotyping Assays (Applied Bio-
systems, Foster City, CA, USA) following the manu-
facturer’s instructions. CYP2D6 is a highly polymorphic
gene with more than 70 different allelic variants. We chose
these star alleles because they are more frequent in the
Asian and Caucasian population (Bradford 2002; Sistonen
et al. 2007; Veiga et al. 2009).
Tamoxifen and its metabolites were measured by liquid
chromatography tandem mass spectrometry (LC-MS/MS)
as described elsewhere (Irvin et al. 2011). Standard curves
and quality controls were run with each sample batch.
The intraday coefficient of variance was lower than 10%
for all compounds, while the inter-day was lower than
15%. An intra-patient assay was not run for each sample
set, but repeated measurement was performed in a subset
of samples. The results show that the intra-sample vari-
ability was lower than 10%.
Statistical methods
We have used our preliminary data to explore the relation-
ship between endoxifen concentrations and recurrence
prior to follow-up being complete on all patients in our
adjuvant trial. In this effort, we designed a nested case–con-
trol study. Our rationale was that using such a small case–
control training data set might allow us to validate any
important trend in a larger, independent data set collected
from our trial patients who will have longer follow-up time
in the future (Pepe et al. 2008). Among the 224 studied
patients we identified 24 patients who had recurrence, and
matched them with 24 non-recurrence controls who were
from the same enrollment hospital, were of the same dis-
ease stage (I-II vs. III), and had a similar enrollment date.












*CYP2D6 alleles not in Hardy Weinberg equilibrium.


















Figure 1 Endoxifen plasma concentrations by CYP2D6 genotype
metabolic status in Filipino (n = 138) and Vietnamese (n = 86)
patients (p = 0.0001 for trend: normal > intermediate > slow).
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mented by Bergstrahl (Bergstralh et al. 1996) and the
follow-up time for the control in each pair was required to
be at least as long as the time to recurrence for the case.
The effect of CYP2D6 genotype metabolic status on
each of the metabolites (tamoxifen, NDMTAM, endoxifen,
and 4-OHTAM) was assessed using a test for linear trend.
The proportion of variance explained by the linear trend
model (r-squared) was also calculated.Table 2 CYP2D6 genotypes
























CYP2D6 allelic frequencies in the two populations were in
Hardy-Weinberg Equilibrium except for *1 and *2 in
Filipinos (Table 1). Frequencies of specific genotypes are
presented in Table 2. On the basis of the genotype-
predicted phenotype, genotypes were categorized as normal
























Table 3 Tamoxifen and metabolites concentrations* in patients with CYP2D6 in 224 Filipino and Vietnamese patients
CYP2D6 Genotype Gene-dose effect
Tamoxifen and Metabolites All (N = 224) Normal (N = 34) Intermediate (N = 107) Slow (N = 83) Variance explained (p-value for trend)
Tamoxifen (TAM) 195.3 ± 240.9 207.7 ± 256.7 167.7 ± 150.5 226.1 ± 316.2 0.003 (0.39)
NDMTAM 353.3 ± 409.0 325.5 ± 371.1 297.0 ± 238.5 437.2 ± 560.6 0.016 (0.060)
Endoxifen 35.4 ± 28.7 48.2 ± 39.7 39.3 ± 26.6 25.0 ± 22.3 0.086 (<0.0001)
4-OHTAM 1.9 ± 1.5 2.2 ± 1.8 1.9 ± 1.2 1.7 ± 1.7 0.010 (0.13)
*Concentrations (+/− S.D.) are all in ng/ml.
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gous for *10 and *41), and slow (homozygous for *10, *41
variants and one or more non-functional null alleles: *3-*6).
The data, presented in Figure 1 and Table 3, show wide
inter-individual variability in endoxifen concentrations.
There was a significant association of reduced endoxifen
plasma concentrations with functionally important CYP2D6
genotypes.
In these data only 10% of the variance in endoxifen
concentrations was explained by CYP2D6 genotype.
CYP2D6 genotypes were also associated with concen-
trations of 4-hydroxytamoxifen, another active meta-
bolite of tamoxifen, although this association was less
strong, consistent with the partial role CYP2D6 plays in
its formation.
Association of Endoxifen with disease recurrence
A trend in the data for the 48 patients in the nested case–
control study showed an unexpected result: high endoxifen
concentrations were associated with higher risk of recur-
rence. We expected that low endoxifen concentrations

















































Endoxifen of the recurrence
Figure 2 Plot of the absolute difference in endoxifen levels between
recurrence member of the matched pair.recurrence. Instead, we found that the greatest increase in
risk was associated with high endoxifen concentrations
(above 70 ng/ml) and that 25% of recurrences had such
high concentrations. A quadratic trend fitted to a Cox pro-
portional hazards regression model stratified by matched
set demonstrated a likelihood ratio p-value of 0.002. The
quadratic variable was created by mean deviating endoxifen
concentrations and squaring the deviation. Because the
endoxifen concentrations were skewed, the high endo-
xifen values gave the highest values for this variable, but
low endoxifen levels also gave values higher than mean
levels, hence the label quadratic effect.
Figure 2 shows the raw data for the 24 matched pairs. It
substantiates the significant quadratic effect found in the
Cox model. The x-axis is the endoxifen concentration of
the recurrence member of the pair, and the y-axis shows
the absolute deviation between endoxifen concentrations
of the two members of each pair. For the recurrences with
high endoxifen concentrations, the absolute deviations are
all large, indicating that the matched controls all had
much lower endoxifen levels. The trend also showed that
when a recurrence had very low endoxifen levels (below75 100 125 150
 member of matched pair (ng/ml)
members of each matched pair by the endoxifen level of the
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a wide J-shaped relationship).
Discussion
The current report is of an exploratory, hypothesis-
generating study. The data here relating CYP2D6 genotypes
and endoxifen concentrations are consistent with previous
reports with respect to genotype associations, inter-patient
variability, and percentage of the inter-patient variability
explained by CYP2D6 metabolic status. What is novel and
provocative are the data suggesting a J-shaped relationship
between endoxifen concentrations in individual patients
and likelihood of recurrence. That the suggested increased
risks of recurrence at low and high (>70 ng/ml) endoxifen
concentrations represent findings which may be validated
in the future are supported by:
i. In the treatment of patients with metastatic breast
cancer, it has been regularly observed that patients
often exhibit a disease “flare” in the first several days
after beginning tamoxifen, suggesting that low
endoxifen concentrations are estrogenic or disease
growth- stimulating.
ii. The incomplete data on the issue of relationships of
blood concentrations of endoxifen and effects. The
challenges have been to assess concentrations at the
effector sites.
iii. The uncertain effects of high-affinity species. We
suggest that for the high affinity endoxifen, the wide
ranges of blood levels may be associated with
remarkably different effects at the receptor sites.
iv. The general observation that despite a strong
predictive relationship between tumoral hormone
receptor status and response to tamoxifen, in even
the best of circumstances responses rates are 60%
only and some patients clearly have immediate
progressive disease in the face of this therapy.
It is estimated that among “normal” CYP2D6 genop-
type carriers, 32% develop steady state endoxifen levels
of >70 ng/ml with tamoxifen 20 mg/day (range 71–
142 ng/ml) (Borges et al. 2006). Our observation there-
fore, if confirmed, will carry significant relevance to the
issue of optimizing use of this treatment worldwide. In
addition, our findings may have important implications
as oral endoxifen is under clinical investigation as a new
treatment for breast cancer (Ahamed et al. 2010).
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